LifeMD (NASDAQ:LFMD) Announces Quarterly Earnings Results

LifeMD (NASDAQ:LFMD - Get Free Report) announced its earnings results on Monday. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02, Zacks reports. The business had revenue of $64.26 million for the quarter, compared to the consensus estimate of $57.43 million. LifeMD updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

LifeMD Stock Down 0.6 %

NASDAQ LFMD traded down $0.03 during trading hours on Friday, reaching $5.63. 675,609 shares of the company were exchanged, compared to its average volume of 804,913. The stock has a market capitalization of $243.67 million, a P/E ratio of -8.83 and a beta of 1.50. LifeMD has a 1 year low of $3.99 and a 1 year high of $12.88. The business's 50 day simple moving average is $5.68 and its 200-day simple moving average is $5.38.

Wall Street Analyst Weigh In

LFMD has been the subject of a number of research analyst reports. HC Wainwright boosted their target price on LifeMD from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday. Lake Street Capital started coverage on shares of LifeMD in a research report on Tuesday, December 10th. They issued a "buy" rating and a $12.00 price target for the company. B. Riley raised shares of LifeMD to a "strong-buy" rating in a research note on Tuesday. Mizuho assumed coverage on shares of LifeMD in a research report on Wednesday, December 4th. They set a "neutral" rating and a $7.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price objective on shares of LifeMD in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, LifeMD presently has a consensus rating of "Buy" and an average target price of $11.43.

Remove Ads

Insider Activity

In other LifeMD news, CEO Justin Schreiber sold 50,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the sale, the chief executive officer now owns 2,653,715 shares of the company's stock, valued at $20,035,548.25. The trade was a 1.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 15.97% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.